EV25
Influenza
Pre-clinicalActive
Key Facts
About Eradivir
Eradivir is a private, preclinical-stage biotech founded in 2020 by renowned drug developer Dr. Philip S. Low. The company's core technology, the BAiT platform, uses small molecules to bridge diseased cells and the innate immune system, aiming for a precise and potent therapeutic effect. With a seasoned leadership team and a validated founder track record, Eradivir is advancing its lead candidate, EV25, for influenza and exploring applications in other diseases like cancer. The company represents a novel approach in immunotherapy, leveraging the advantages of small molecules to potentially overcome limitations of biologic therapies.
View full company profileTherapeutic Areas
Other Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| PanCytoVir™ (oral probenecid) | TrippBio | IND Submitted |
| Mimotopes-004 | Mimotopes | Preclinical |
| Next-Gen / Universal Flu Vaccines | CSL Seqirus | Research / Early Clinical |
| Oseltamivir 75 mg | MSN Laboratories | Commercial |
| AI Programme - Influenza | Poolbeg Pharma | Discovery |
| Influenza Antibodies | new/era/mabs | Research/Pre-clinical |
| Influenza Countermeasure Program | DynPort Vaccines | Not Specified |
| Influenza Vaccine | Medigen | Preclinical |
| Nasal Influenza Vaccine | Abera Bioscience | Pre-clinical |
| Zapnometinib (ATR-002) | Atriva Therapeutics | Phase 2 |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| Influenza Program | Arisan Therapeutics | Preclinical |